WO2013057422A1 - Derives aminosteroidiens anti-diabetiques - Google Patents
Derives aminosteroidiens anti-diabetiques Download PDFInfo
- Publication number
- WO2013057422A1 WO2013057422A1 PCT/FR2012/052359 FR2012052359W WO2013057422A1 WO 2013057422 A1 WO2013057422 A1 WO 2013057422A1 FR 2012052359 W FR2012052359 W FR 2012052359W WO 2013057422 A1 WO2013057422 A1 WO 2013057422A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cholestan
- group
- alkyl
- aryl
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
Definitions
- the present invention relates to novel aminosteroid derivatives, and their use in particular in the treatment of type 2 diabetes and insulin resistance.
- T2DM type 2 diabetes
- the very first symptom of type 2 diabetes is desensitization to insulin in the liver, skeletal muscle and adipose tissue.
- the increase in insulinemia (as after a meal) then no longer allows sufficient uptake of sugar by the muscles and fat cells, nor the stopping of the hepatic production of sugar.
- This process, called insulin resistance is the first step in the development of hyperglycemia.
- Skeletal muscle and adipose tissue are the main tissues responsible for storing blood sugar after a meal, and the GLUT4 glucose transporter in these tissues is responsible for the uptake of blood sugar.
- the complications associated with type 2 diabetes are severe (blindness, kidney failure, heart disease), and can lead to the death of the patient.
- thiazolidinediones improve muscle and adipose tissue sensitivity for insulin, but have significant side effects (edema, weight gain, and heart problems) .
- Another therapeutic approach is to administer insulin.
- the major disadvantage of insulin is that it can only be given by injection.
- some patients become insensitive to insulin administrations.
- Other therapeutic approaches use glucagon-like peptide-1 analogues (GLP-1, such as exenatide) and amylin mimetics (such as pramlintide).
- GLP-1 glucagon-like peptide-1 analogues
- amylin mimetics such as pramlintide
- trodusquamine of formula (MSI-1436), proposed to treat obesity and diabetes (cf patent application US2009 / 0105204).
- the inventors now propose a new family of aminosteroid derivatives substituted in the 3 and 6 positions, which show a cellular uptake effect of sugar and can therefore be used in particular for the treatment of type 2 diabetes and insulin resistance.
- the present invention thus provides aminosteroid derivatives of formula (I):
- the preferred compounds are 6 -sperminocholestan 3 ⁇ - ⁇ and 6p-spermidinocholesten-3p-ol, preferably in the form of hydrochlorides.
- the invention is directed to the compounds described herein as drugs.
- Another object of the invention is therefore a pharmaceutical composition comprising an aminosteroid derivative of formula (I) and a pharmaceutically acceptable vehicle.
- Such a composition is particularly useful in the treatment of type 2 diabetes, to reduce hyperglycemia and its complications, and in the treatment of insulin resistance.
- Figure 1A is a graph which shows the measurement of GLUT4 at the surface of the plasma membrane (MP), as a function of time, in the presence of insulin ( ⁇ ), ST10 (50 ⁇ ), or both handsets.
- Figure 1B is a graph showing the increase in GLUT4 at the plasma membrane (MP) surface as a function of the ST10 compound concentration.
- Figure 1C is a histogram showing that the increase of GLUT4 at the surface of the plasma membrane (MP) is greater in the presence of STIO than in the presence of trodusquemine (MSI).
- Figure 1D shows the percentage of GLUT4 on the surface of cells according to the aminosterol considered, and the presence (black bars) or absence (white bars) of insulin.
- the dots represent the values observed without aminosterol, in the presence or absence of insulin.
- Figure 2 is a graph showing that glucose uptake into adipocytes is increased by STIO for all insulin concentrations tested.
- Figure 3A is a graph showing the effect of insulin and STIO on GLUT4 level on the plasma membrane.
- Figure 3B is a conversion of Figure 3A where the values are expressed as a function of the relative difference between the minimum and maximum signals. This figure shows that STIO also increases the sensitivity of cells to insulin.
- Figure 4 is a graph showing the effect of STIO on plasma membrane GLUT4 level in insulin-resistant cells compared to the effect in insulin-sensitive cells.
- the black bars correspond to the presence of STIO and the white bars to its absence.
- Figure 5 is a graph showing the in vivo effect of ST20 treatment on mouse glucose after Glucose Tolerance Test (GTT) injection.
- Figure 6 is a graph showing the in vivo effect of ST20 treatment on mouse glucose after Insulin Tolerance Test (ITT).
- Figure 7 is a graph showing the in vivo effect of ST20 treatment on glucose in obese mice after glucose dose injection (GTT).
- Figures 8A and 8B are graphs that show the in vivo effect of ST20 treatment on food intake and weight gain of obese mice. The treatment is started on day 0.
- the present invention relates to novel aminosteroid derivatives of formula (I):
- i is chosen from a hydroxyl group and a polyamine chain of formula -NR 3 R 4 , with
- R 3 - (AX) P -A-NR 6 R 7 , where each A, identical or different, is an alkyl chain comprising 1 to 7 carbons, each carbon being independently optionally substituted by at least one alkyl, aryl or ester group; each X, identical or different, is an oxygen atom, an NR 5 group or a single bond, each of R 5 is independently selected from hydrogen, alkyl, aryl and ester;
- R6 and R7 are independently selected from hydrogen, alkyl, aryl and ester, alternatively NR6R7 may be nitrogen heterocycle, p is an integer selected from 1 to 4 (inclusive),
- R 4 is chosen from a hydrogen atom, an alkyl group, an aryl group and an ester group, 2 has the same definition as R lt R x and R 2 are selected independently from each other, and at least one of R x and R 2 is a polyamino chain of formula -NR 3 R 4 as defined above.
- the dotted line designates either a single bond or a double bond.
- each group A (respectively X) is chosen independently.
- the present invention also includes the optical and geometric isomers of the derivatives of formula (I) at the level of the atoms whose geometry is not fixed in formula (I), their racemates, their tautomers, their pharmaceutically acceptable salts, their hydrates and their mixtures.
- the derivatives of formula (I) defined as above having a sufficiently acidic function or a sufficiently basic function, or both, can include the corresponding salts of organic or inorganic acid or organic or inorganic base pharmaceutically acceptable.
- the derivatives of formula (I) can have basic nitrogen atoms which can be monosalified or disalified by organic or inorganic acids.
- pharmaceutically acceptable salts refers to the relatively non-toxic, inorganic and organic acid addition salts, and base addition salts, of the compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds.
- the acid addition salts can be prepared by separately reacting the purified compound in its purified form with an organic or inorganic acid and isolating the salt thus formed.
- acid addition salts are the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate and citrate salts.
- the acid addition salts may also be prepared by separately reacting the purified compound in its acid form with an organic or inorganic base and isolating the salt thus formed.
- Acidic addition salts include amine and metal salts. Suitable metal salts include sodium, potassium, calcium, barium, zinc, magnesium and aluminum salts. Sodium salts and potassium are preferred.
- Suitable basic inorganic addition salts are prepared from metal bases which include sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide .
- Suitable base amino acid addition salts are prepared from amines which have sufficient alkalinity to form a stable salt, and preferably include those amines which are often used in medicinal chemistry because of their low toxicity and acceptability.
- ammonia ethylenediamine, N-methylglucamine, lysine, arginine, ornithine, choline, ⁇ , ⁇ '-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris (hydroxymethyl aminomethane, tetramethylammonium hydroxide, triethylamine, dibenzylamine, ephenamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, ethylamine, basic amino
- R x is a hydroxyl group.
- R 2 is a polyamine chain of formula -NR 3 R 4 as defined above.
- each X is an oxygen atom or an NR 5 group.
- all the X of the polyamine chain are NR 5 groups.
- R6 and R7 are independently chosen from a hydrogen atom, an aryl group and an ester group.
- the derivative of formula (I) is chosen from:
- the derivative of formula (I) is 6 ⁇ -sperminocholestan 3 ⁇ - ⁇ or 6p-spermidinocholesten-3p-ol, of the following formulas:
- alkyl group denotes, in the present invention, a hydrocarbon group, linear, branched or cyclic, saturated, C 1 -C 8, preferably C 1 -C 4, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, ieri-butyl, pentyl, neopentyl, n-hexyl, n-octyl.
- the alkyl groups may optionally have one or more substituents chosen in particular from a halogen atom, a hydroxyl group, an amino group, an alkoxyl (-O-alkyl), thiol, thioether (-S-alkyl), nitro, cyano group. , sulfuric (O-SO 3 H) and ester (-CO 2 -alkyl).
- aryl group is meant in the present invention a mono-, bi- or tri-cyclic aromatic hydrocarbon group, optionally interrupted by at least one heteroatom, in particular O, S and / or N.
- the aryl group is a monocyclic or bicyclic aromatic hydrocarbon system having 6 to 18 carbon atoms, more preferably 6 carbon atoms. Mention may be made, for example, of phenyl, naphthyl and biphenyl groups. When interrupted by hetero atoms, the aryl groups include pyridyl, imidazoyl, pyrrolyl and furanyl rings.
- the aryl groups may optionally have one or more substituents, chosen in particular from a halogen atom, an alkyl group as defined above, an alkoxyl (-O-alkyl), thiol, thioether (-S-alkyl) radical, hydroxyl, nitro, cyano and ester (-CO 2 -alkyl).
- substituents chosen in particular from a halogen atom, an alkyl group as defined above, an alkoxyl (-O-alkyl), thiol, thioether (-S-alkyl) radical, hydroxyl, nitro, cyano and ester (-CO 2 -alkyl).
- a halogen atom for example, pyrrolidine, pyrrolidone, morpholine, imidazole and piperazine heterocycles may be mentioned.
- halogen atom denotes a chlorine, bromine, iodine or fluorine atom.
- the preferred method of preparation utilizes a titanium reductive amination reaction of the corresponding ketosteroids under mild conditions (ambient temperature and atmospheric pressure) as illustrated below.
- the inventors have been able to show a sustained reduction in blood glucose.
- the compounds of the invention are therefore useful for providing better control of an individual's blood glucose level.
- the compounds of the invention are useful for decreasing insulin resistance.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising an aminosteroid derivative as defined above and a pharmaceutically acceptable vehicle.
- the compounds or compositions according to the invention can be administered in different ways and in different forms. Thus, they can be administered systemically, orally, by inhalation or by injection, for example intravenously, intramuscularly, subcutaneously, trans-dermal, intra-arterial, etc., the intravenous routes, intramuscular, subcutaneous, oral and inhalation being preferred.
- the compounds are generally packaged in the form of liquid suspensions, which can be injected by means of syringes or infusions, for example. In this respect, the compounds are generally dissolved in saline, physiological, isotonic, buffered, etc.
- compositions may contain one or more agents or vehicles chosen from dispersants, solubilizers, stabilizers, preservatives, etc.
- agents or vehicles that can be used in liquid and / or injectable formulations include methylcellulose, hydroxymethylcellulose, carboxymethylcellulose, polysorbate 80, mannitol, gelatin, lactose, vegetable oils, acacia, etc.
- the compounds can also be administered in the form of gels, oils, tablets, suppositories, powders, capsules, aerosols, etc., possibly by means of dosage forms or devices providing sustained and / or delayed release.
- an agent such as cellulose, carbonates or starches is advantageously used.
- the flow rate and / or the dose administered can be adapted by those skilled in the art depending on the patient, the pathology concerned, the mode of administration, etc.
- the compounds are administered at doses ranging from 0.1 ⁇ g to 100 mg / kg of body weight, more generally from 0.1 to 20 mg / kg, typically between 1 and 10 mg / kg.
- delayed or extended systems may be used.
- the invention also relates to a method of treating type 2 diabetes or insulin resistance, by administering to a subject suffering from such a pathology an effective amount of one of the compounds according to the invention. .
- this is a subject who has become insensitive to insulin.
- the compounds of the invention are also useful for treating hyperglycemia (ie, reducing or preventing the occurrence of hyperglycemia), or for preventing or treating a complication of hyperglycemia.
- Said complications include retinopathies, neuropathies, nephropathies, cardiovascular lesions, lesions in the feet (diabetic foot).
- the compounds of the invention are further useful for reducing the weight of an individual, particularly an overweight individual, preventing weight gain, or preventing or treating obesity.
- the compounds of the invention are also useful as appetite suppressants or appetite suppressants. Finally, the compounds of the invention are useful for improving the physical performance of an individual, in particular by their action promoting a rapid penetration of sugar into the cells.
- treatment refers to the preventive, curative and palliative treatment, as well as the management of the patients (reduction of the suffering, improvement of the lifespan, slowing of the progression of the disease , etc.).
- the compound of the invention may be administered as sole active ingredient, or as sole anti-diabetic, or in combination with other active ingredients, in particular with other anti-diabetics.
- the treatment can thus be carried out in combination with other agents or chemical or physical treatments.
- the compounds according to the invention can then be packaged and administered in a combined, separate or sequential manner with respect to other therapeutic agents or treatments.
- the treatments and medicaments of the invention are particularly intended for humans.
- the present invention also relates to the use of at least one compound as defined above for the preparation of a pharmaceutical composition for treating type 2 diabetes or one of the pathologies mentioned above.
- the aminosteroids were all produced according to the same procedure.
- 3 equivalents of amine (0.6910 ⁇ 3 mol) are dissolved in 5 ml of MeOH, then 87 ⁇ of Ti (0 / ' pr) 4 (0.3010 ⁇ 3) are added. mol).
- the mixture was added 100 mg of 6-kétocholestanol (0.2310 -3 mol).
- the flask is placed at -78 ° C. and then 11 mg of NaBH 4 (0.23 ⁇ 10 -3 mol) are added. 2 hours later, 1 mL of water is added to stop the reaction.
- GLUT4 glucose transporter One of the key players in insulin-induced sugar uptake by myocytes and adipocytes is the GLUT4 glucose (sugar) transporter.
- GLUT4 glucose transporter When insulin binds to its receptor on the surface of these cells, or during muscle contraction, intracellular signaling pathways are activated, leading to the translocation of GLUT4 from its intracellular storage compartment to the plasma membrane, where it allows the entry of the sugar from the extracellular medium.
- GLUT4 therefore plays an important role in carbohydrate homeostasis and therefore in T2DM.
- the 3T3-L1 adipocytes are stimulated for 20 minutes with aminosteroids (50 ⁇ ), in the presence or absence of insulin (1 nM), and are labeled for GLUT4 on the surface of the cells. The percentage of GLUT4 on the surface of the cells is then determined.
- a comparison is made between compound 6 -sperminocholestan 3 ⁇ - ⁇ (compound ST10) and trodusquamine (MSI-1436).
- the results shown in Figures 1A-1C, show that ST10, but not trodusquamine, increases insulin efficiency on translocation of GLUT4 in 3T3-L1 adipocytes.
- Figure 1D shows that other compounds of the invention have such an interesting effect.
- 3T3-L1 adipocytes were incubated in the presence or absence of insulin, at different concentrations, and in the presence or absence of 6 -sperminocholestan 3 ⁇ - ⁇ (compound ST10). Glucose uptake was measured and expressed as a percentage of maximum uptake in the absence of aminosteroid.
- Figure 2 shows the results obtained.
- the aminosteroid derivative according to the invention increases the uptake of glucose into the adipocytes.
- Example 4 Effect of the derivative ST10 on the sensitivity of adipocytes to insulin
- the adipocytes were stimulated for 20 min with insulin, in the presence (black bars) or absence (white bars) of 6 -sperminocholestan 3 ⁇ - ⁇ (compound ST10).
- the amount of GLUT4 on the cell surface was determined ( Figure 4). Insulin-resistant cells show a decrease in the action of insulin, but in these cells the aminosteroid according to the invention also increases the effect of insulin.
- mice were treated, for two weeks, with the derivative ST20 at doses of: 0 mg / kg / day, 5 mg / kg / day, 10 mg / kg / day or 10 mg / kg both days.
- the blood glucose levels of the mice were measured up to 120 minutes after the glucose injection. As shown in Figure 5, the increase in blood glucose is due to glucose injection and the subsequent decrease in blood glucose is due to the action of insulin.
- blood glucose decreased more rapidly than for the group of untreated mice. Treatment with the derivative ST20 thus potentiates the effect of insulin.
- Example 7 Effect of ST20 Derivative on Glucose in Obese Mouse Glucose Tolerance Test (GTT)
- mice Four groups of mice were formed: the HFD group (high fat diet) having followed for 12 weeks a high fat diet and unlimited food, the group HFD ST (high fat diet sterol treatment) having followed the same diet and having been treated for one week with the derivative ST20 (10 mg / kg every two days), the group HFD PF (high fat diet "pair feeding") having a diet equivalent to the amount of food consumed by the group HFD ST and the norm group (normal) having a normal diet.
- the blood glucose levels of the mice were measured up to 120 minutes after the glucose injection. As shown in Figure 7, the increase in blood glucose is due to glucose injection and the subsequent decrease in blood glucose is due to the action of insulin.
- the difference in glycemia between the HFD and norm groups shows the insulin resistance of HFD mice.
- the HFD ST group has a significantly greater decrease in blood glucose than the HFD and HFD PF groups.
- Treatment with the ST20 derivative is effective in obese mice and decreases insulin resistance.
- mice Groups of obese mice were formed as in Example 7. In these obese mice, the injection of the ST20 derivative (at a dose of 10 mg / kg every other day) caused a decrease in food intake (FIG. 8A), which lasted more than three weeks.
- the pairs of mice fed controls (HFD PF group) received similar amounts of food. The reduction in food intake led to a marked decrease in body weight (Figure 8B), which persisted throughout the duration of the experiment (5 weeks).
- the body weight of the pairs of fed mice (HFD PF group) decreased similarly to those of the treated mice (ST HFD group), indicating that the effect of the ST20 derivative on body weight is due to the decrease in food.
- injection of ST20 in obese mice induces a sustained reduction in body weight due to reduced food intake.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2852214A CA2852214A1 (fr) | 2011-10-17 | 2012-10-16 | Derives aminosteroidiens anti-diabetiques |
EP12787771.0A EP2768840A1 (fr) | 2011-10-17 | 2012-10-16 | Derives aminosteroidiens anti-diabetiques |
US14/352,220 US20140249122A1 (en) | 2011-10-17 | 2012-10-16 | Anti-diabetic aminosteroid derivatives |
JP2014536311A JP2014532077A (ja) | 2011-10-17 | 2012-10-16 | 抗糖尿病アミノステロイド誘導体 |
CN201280059724.2A CN104254539A (zh) | 2011-10-17 | 2012-10-16 | 抗糖尿病的氨基甾族化合物衍生物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1159377A FR2981351A1 (fr) | 2011-10-17 | 2011-10-17 | Derives aminosteroidiens anti-diabetiques |
FR1159377 | 2011-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013057422A1 true WO2013057422A1 (fr) | 2013-04-25 |
Family
ID=47191953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2012/052359 WO2013057422A1 (fr) | 2011-10-17 | 2012-10-16 | Derives aminosteroidiens anti-diabetiques |
Country Status (7)
Country | Link |
---|---|
US (1) | US20140249122A1 (fr) |
EP (1) | EP2768840A1 (fr) |
JP (1) | JP2014532077A (fr) |
CN (1) | CN104254539A (fr) |
CA (1) | CA2852214A1 (fr) |
FR (1) | FR2981351A1 (fr) |
WO (1) | WO2013057422A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE1027157B9 (fr) * | 2019-08-01 | 2020-11-03 | Dendrogenix | Composition de dérivés de stérols pour son utilisationdans le traitement d’une pathologie neuronale liée à une hypoxie et/ou à une hypoglycémie et composition correspondante |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2047880A1 (en) * | 1969-06-16 | 1971-03-19 | Serdex | 6-amino-stigmas tan-3-ols and-cholestan-3-ols - hypochlolesteremic agents |
US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
US5721226A (en) | 1993-03-10 | 1998-02-24 | Magainin Pharmaceuticals Inc. | Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives |
WO2009032321A2 (fr) * | 2007-09-06 | 2009-03-12 | Genaera Corporation | Procédé de traitement du diabète |
US20090105204A1 (en) | 1996-05-17 | 2009-04-23 | Michael Zasloff | Therapeutic Uses for Aminosterol Compounds |
-
2011
- 2011-10-17 FR FR1159377A patent/FR2981351A1/fr not_active Withdrawn
-
2012
- 2012-10-16 JP JP2014536311A patent/JP2014532077A/ja active Pending
- 2012-10-16 CA CA2852214A patent/CA2852214A1/fr not_active Abandoned
- 2012-10-16 EP EP12787771.0A patent/EP2768840A1/fr not_active Withdrawn
- 2012-10-16 WO PCT/FR2012/052359 patent/WO2013057422A1/fr active Application Filing
- 2012-10-16 US US14/352,220 patent/US20140249122A1/en not_active Abandoned
- 2012-10-16 CN CN201280059724.2A patent/CN104254539A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2047880A1 (en) * | 1969-06-16 | 1971-03-19 | Serdex | 6-amino-stigmas tan-3-ols and-cholestan-3-ols - hypochlolesteremic agents |
US5192756A (en) | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
US5721226A (en) | 1993-03-10 | 1998-02-24 | Magainin Pharmaceuticals Inc. | Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives |
US5733899A (en) | 1993-03-10 | 1998-03-31 | Magainin Pharmaceuticals Inc. | Method for treating infection using steroid based pharmaceutical compositions |
US20090105204A1 (en) | 1996-05-17 | 2009-04-23 | Michael Zasloff | Therapeutic Uses for Aminosterol Compounds |
WO2009032321A2 (fr) * | 2007-09-06 | 2009-03-12 | Genaera Corporation | Procédé de traitement du diabète |
Non-Patent Citations (3)
Title |
---|
CHOUCAIR B ET AL: "Synthesis of spermidinylcholestanol and spermidinylcholesterol, squalamine analogues", TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 60, no. 50, 6 December 2004 (2004-12-06), pages 11477 - 11486, XP004628608, ISSN: 0040-4020, DOI: 10.1016/J.TET.2004.09.055 * |
PINHAS H ET AL: "6-Amino derivatives of stigmastanol and cholestanol", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 14, no. 11, 1 January 1971 (1971-01-01), pages 1048 - 1049, XP002220449, ISSN: 0022-2623, DOI: 10.1021/JM00293A006 * |
S.M. BERGE ET AL.: "Pharmaceutical Salts", J. PHARM. SCI, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: doi:10.1002/jps.2600660104 |
Also Published As
Publication number | Publication date |
---|---|
US20140249122A1 (en) | 2014-09-04 |
EP2768840A1 (fr) | 2014-08-27 |
JP2014532077A (ja) | 2014-12-04 |
CA2852214A1 (fr) | 2013-04-25 |
CN104254539A (zh) | 2014-12-31 |
FR2981351A1 (fr) | 2013-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2955987C (fr) | Triterpenoides synthetiques et procedes d'utilisation dans le traitement de maladies | |
FR2774591A1 (fr) | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie | |
MX2013013200A (es) | Combinación farmacéutica para uso en la inducción de pérdida de peso en pacientes que padecen diabetes de tipo 2 y/o en la prevención del aumento de peso en pacientes que padecen diabetes de tipo 2. | |
MXPA06009588A (es) | Lactamas como inhibidores peptidomimeticos restringidos mediante su configuracion. | |
KR20190027866A (ko) | 제2형 당뇨병 치료를 위한 아드레날린 수용체 작용제들의 조합 | |
EP3925610A1 (fr) | Composition et procédé de traitement de troubles métaboliques | |
FR2797767A1 (fr) | Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances | |
US20080262071A1 (en) | Pindolol for the Treating Premenstrual Syndrome and Premenstrual Dysphoric Disorder | |
FR2822464A1 (fr) | Derives biguanides et leurs applications en therapeutique | |
WO2013057422A1 (fr) | Derives aminosteroidiens anti-diabetiques | |
FR2849598A1 (fr) | Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans | |
HU199394B (en) | Process for producing fluoroallylamine monoamineoxidase inhibitors | |
KR20080061431A (ko) | 에이디피-라이보실 사이클레이즈 억제제를 이용한 고혈압 및 당뇨병성 신증의 치료제 | |
US20060105965A1 (en) | Method for enhancing energy levels and reducing the effects of stress using nutraceutical formulations | |
US20020151581A1 (en) | Glucose and lipid lowering compounds | |
JP3944393B2 (ja) | インスリン抵抗性および糖尿病のための、コリン塩基とコハク酸とを含む相乗効果のある組成物 | |
WO2002012177A1 (fr) | Composition de metformine avec de l'acide succinique et leurs sels et procede pour traiter le diabete | |
AU2005283829A1 (en) | Pindolol for the treating premenstrual syndrome and premenstrual dysphoric disorder | |
KR20010080428A (ko) | 글루코스 및 지질을 저하시키는 화합물 | |
RU2627610C2 (ru) | Композиция аминокислот для профилактики и лечения отравлений метанолом | |
JP2020520904A (ja) | 薬剤、組成物、及びそれに関連する方法 | |
Del Prato | Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes | |
KR20090075269A (ko) | 비만 예방 및 치료용 조성물 | |
RU2203656C1 (ru) | Фармацевтическая композиция с антидиабетическим действием на основе производного оксованадия и способ его получения | |
EA028995B1 (ru) | Соль тезофензина и оптически активных ацетиламинокислот, их применение для лечения и/или профилактики нарушений, связанных с ожирением |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12787771 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2852214 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014536311 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14352220 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2012787771 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012787771 Country of ref document: EP |